THE US Food and Drug
Administration (FDA) has released
a trials snapshot of TAGRISSO, a
drug used to treat patients with
advanced non-small cell lung
cancer (NSCL).
Clinical trials for the drug were
conducted globally on a total of 411
patients across 10 countries with
NSCL, all with the T790M mutation
whose condition worsened
following treatment with EGFRblocking
medication.
Taken as a tablet by mouth once
a day, TAGRISSO was found to have
a “significant effect on reducing
tumour size on over half of patients
who were treated”.The above article was sent to subscribers in Pharmacy Daily's issue from 04 Jan 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Jan 16
PEAK pharmacy bodies are calling on the Australian Government to extend the new Commonwealth Prac Payment to pharmacy students, citing the challenges of “placement poverty” in unpaid practical placements.
AFT Pharmaceuticals is set to develop a topical treatment for keloid and hypertrophic scarring in partnership with NZ’s Massey Ventures, the commercialisation arm of Massey University, and the Gillies McIndoe Research Institute.
THE Pharmaceutical Society of Australia (PSA) awarded Brooke Shelly the prestigious 2024 PSA MIMS Credentialed Pharmacist of the Year award last Fri at the Credentialed Pharmacist Conference (CPC24) (PD breaking news).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.